Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day
For those with type 2 diabetes, particularly when combined with other diabetes medications, GLP-1's may increase the risk of hypoglycemia (low blood sugar)
To date, we have not found any compound of any particle size that we cannot deliver through physiological tissue to create a positive effect both locally and systemically
Common Adverse Events Researchers Track in Phase 2 and Phase 3 Across retatrutide side effects clinical trials queries, the same adverse-event cluster appears repeatedly: nausea, vomiting, diarrhea, constipation, decreased appetite, abdominal pain, back pain, and fatigue or tiredness
Semaglutide is a GLP-1 receptor agonist, which is just a technical way of saying that it mimics a hormone in your body that helps regulate appetite and blood sugar